Objective: To systematically evaluate the efficacy of ranibizumab, aflibercept and conbercept in the treatment of patients with diabetic macular edema (DME) and to provide evidence for the selection of the best treatment option for patients with DME. Methods: The PubMed, Cochrane, EMbase, Web of science, Wanfang, VIP and CNKI databases were searched for the efficacy of anti-vascular endothelial growth factor (VEGF) drugs in patients with DME, including best corrected visual acuity (BCVA) and central subfield thickness (CST). The retrieval time limit was from the establishment of the database to July 2022. After two researchers independently screened the literature, extracted the relevant data and evaluated the methodological quality, meta-analysis was performed using STATA16.0, ADDIS1.16.7 and Revmann5.4 software. Results: A total of 7 studies were finally included in this study, and after excluding outcomes outside the analysis, a total of 1103 eyes were included. Meta-analysis results showed that after 1 year, there was a statistically significant difference in BCVA improvement between ranibizumab and aflibercept [-0.02(-0.03, 0.00), P＜0.05], but ranibizumab and conbercept [0.06 (-0.02, 0.15), P=0.14] and aflibercept versus conbercept [0.00 (-0.13, 0.13), P＞0.05] were not statistically significant. Conclusion: Among the three anti-VEGF drugs, aflibercept has the best effect in improving BCVA, while ranibizumab has the best effect in reducing macular CST.
DENG Huixue
,
LIU Sha
,
LI Shuxia
,
WANG Bin
. Network Meta-analysis of the efficacy of different anti-vascular endothelial growth factor drugs for diabetic macular edema[J]. Journal of Baotou Medical College, 2023
, 39(8)
: 22
-27
.
DOI: 10.16833/j.cnki.jbmc.2023.08.005
[1] 中华医学会糖尿病学分会视网膜病变学组. 糖尿病视网膜病变防治专家共识[J].中华糖尿病杂志, 2018, 10(4):241-247.
[2] 中华医学会眼科学会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2014年)[J].中华眼科杂志, 2014, 50(11):851-865.
[3] Bandello F, Battaglia Parodi M, Lanzetta P, et al. Diabetic macular edema[J].Dev Ophthalmol, 2017,58:102-138.
[4] Sahni J, Patels S, Dugelp U, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-a with faricimab in diabetic macular edema: boulevardphase 2 randomized trial[J].Ophthalmology, 2019,126(8):1155-1170.
[5] Altınelm G, Acikalin B, Alism G, et al. Comparison of the efficacy and safety of anti-VEGF monotherapy versus anti-VEGF therapy combined with subthreshold micropulse laser therapy for diabetic macular edema[J].Lasers Med Sci, 2021,36(7):1545-1553.
[6] Krick TW, Bressler NM. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network[J].Curr Opin Ophthalmol, 2018,29(3):199-205.
[7] Schmidt-erfurth U, Garcia-arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the European society of retina specialists (EURETINA)[J].Ophthalmologica, 2017,237(4):185-222
[8] Wells JA, Glassman AR, Ayala AR, et al. Diabetic Retinopathy Clinical Research Network.Aflibercept, Bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial[J].Ophthalmology, 2016, 123(6):1351-1359.
[9] Holbach B, Zeman F, Helbig H, et al. Ranibizumab and aflibercept for diabetic macular edema-retrospective study with real-life data after 12 months[J].Ophthalmologe, 2020,117(7):687-692.
[10] Plaza-ramos P, Borque E, GarcíA-layana A. Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice[J].PLoS One, 2019,14(10):e0223793.
[11] Gabriellep H, Nguyen V, Creuzot-garcher C, et al. Three-year treatment outcomesof liberceptversusranibizumabfor diabeticmacularedema: data from the fight retinal blindness! registry[J].Retina, 2022,42(6):1085-1094.
[12] Bhandari S, Nguyen V, Fraser-bell S, et al. Ranibizumab or aflibercept for diabetic macular edema: comparison of 1-year outcomesm the fight retinal blindness! registry[J].Ophthalmology, 2020,127(5):608-615.
[13] 程岩, 刘国英. 雷珠单抗与康柏西普玻璃体腔注射治疗糖尿病性黄斑水肿的临床疗效及安全性对比[J].反射疗法与康复医学, 2021, 2(22):77-80.
[14] 黄玉娟, 孔祥斌, 周立军, 等. 三种不同抗血管内皮生长因子药玻璃体腔内注射治疗累及黄斑中心凹的糖尿病性黄斑水肿的效果[J].中国医药科学, 2022, 12(8):21-26, 59.
[15] Pham B, Thomas SM, Lillie E, et al. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis[J].BMJ Open, 2019 May 28,9(5):e022031.
[16] Diabetic Retinopathy Clinical Research Network. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema[J].Ophthalmology, 2007,114(3):525-536.
[17] Romero-aroca P, Baget-bernaldiz M, Pareja-rios A, et al. Diabetic macular edema pathophysiology: vasogenic versus inflammatory[J].J Diabetes Res, 2016,2016:2156273.
[18] Kodjikian L, Bellocq D, Bandello F, et al. First-line treatment algorithm and guidelines in center-involving diabetic macular edema[J].Eur J Ophthalmol, 2019,29(6):573-584.
[19] 侯宝杰, 赵杰, 徐青. 抗血管内皮生长因子药种类及其眼科应用[J].武警医学, 2017, 28(4):325-328.
[20] Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab[J].Angiogenesis, 2012,15(2):171-185.
[21] Zhang M, Yu DC, Yang C, et al. The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization[J].Pharm Res, 2009,26(1):204-210.
[22] Wang X, Bove AM, Simone G, et al. Molecular bases of VEGFR-2-Mediated physiological function and pathological role[J].Front Cell Dev Biol, 2020,8:599281.
[23] The Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema[J].Ophthalmology, 2010,117(6):1064-1077.e35.
